Mariantonia Nacchio

Oct 31, 2023 | mdpi.com | Caterina de Luca |Francesco Pepe |Gianluca Russo |Mariantonia Nacchio

1. IntroductionIn recent decades, personalized medicine has laid the basis for a novel therapeutical option for solid-tumor patients [1,2]. Currently, target therapy is routinely available for the clinical administration of several solid-tumor patients, including metastatic colorectal cancer (mCRC), melanoma (MM), non-small cell lung cancer (NSCLC), gastrointestinal stromal tumor (GIST), and breast cancer (BC) patients [3,4,5,6,7,8,9].